Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer | Latest News RSS feed

Study: Drug, Chemo Combo Double Survival In Metastatic Lung Cancer - Latest News

Anti-PD-L1 Immunotherapy Plus ABRAXANE ® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast ...

First Phase III study to demonstrate a statistically significant progression-free survival improvement in first-line metastatic ... of a treatment regimen; the other studies evaluated this investigati... read more

FDA Approves Xtandi for Non-Metastatic Castration-Resistant Prostate Cancer

The Food and Drug Administration (FDA) has approved Xtandi (enzalutamide) for the treatment of patients with non-metastatic ... two-drug combination as ADT alone. The study also measured the time unti... read more

Metastatic HR+ Breast Cancer: Developments and Approvals

And this study also showed similar benefits, roughly a 13-month progression-free survival with endocrine therapy alone and roughly double ... combination with an aromatase inhibitor in women who were ... read more

Looking for another news?

Celgene Reports Positive Data on Tecentriq, Abraxane Study

Celgene Corporation CELG announced positive results from a late-stage study on oncology drug ... as part of a treatment regimen. The other studies in the program evaluated the experimental combination ... read more

Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

Pivotal FLAURA study ... best treatment first, and Tagrisso has shown to significantly extend progression-free survival and improve treatment of central nervous system metastases as a first-treatment ... read more

Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?

[2] Approximately 57% of patients with NSCLC present with metastatic ... survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-p... read more

FDA Grants Priority Review to Keytruda-Chemo Combo for Metastatic NSCLC

The U.S. Food and Drug Administration (FDA) has agreed to review a combination of Keytruda (pembrolizumab) and chemotherapy as first-line treatment for metastatic ... program in lung cancer, we are co... read more

Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer

Bristol-Myers Squibb Company BMY announced that the FDA granted approval to the combination of its blockbuster immuno-oncology drug Opdivo ... deficient (dMMR) metastatic colorectal cancer (mCRC) that ... read more

FDA Approves Additional Breast Cancer Indications for Kisqali

In addition, Kisqali has also been approved in combination with fulvestrant to treat postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer ... study was progression ... read more

Atezolizumab Regimen Extends PFS in Frontline Nonsquamous NSCLC

“The IMpower132 study showed Tecentriq plus chemotherapy prolonged the time people with this type of advanced lung cancer lived ... The double-blind phase III KEYNOTE-189 study accrued 616 patients wi... read more

PARP Inhibitors May Bring New Hope to Patients With Small Cell Lung Cancer

PARP inhibitors are approved by the Food and Drug Administration for the treatment of certain breast and ovarian cancers. But could they one day be given the green light to help patients with the dead... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us